This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Laurentiis, M. Articles by De Placido, S. Search for Related Content PubMed PubMed Citation Articles by De Laurentiis, M. Articles by De Placido, S. Related Articles Related Correspondence Social Bookmarking                            What's this?

Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials

Michele De Laurentiis, Giuseppe Cancello, Diego D'Agostino, Mario Giuliano, Antonio Giordano, Emilia Montagna, Rossella Lauria, Valeria Forestieri, Angela Esposito, Lucrezia Silvestro, Roberta Pennacchio, Carmen Criscitiello, Agnese Montanino, Gennaro Limite, Angelo Raffaele Bianco, Sabino De Placido

From the Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università di Napoli "Federico II"; Dipartimento di Chirurgia Generale, Oncologica e Videoassistita, Università di Napoli "Federico II", Napoli, Italy

Corresponding author: Michele De Laurentiis, MD, PhD, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università "Federico II", via Sergio Pansini, 5, 80131, Napoli, Italy; e-mail: delauren{at}unina.it; e-mail: michele.delaurentiis{at}unina.it

Purpose We conducted a meta-analysis of randomized trials that evaluated the efficacy of incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC). We aimed to determine whether this approach improves disease-free survival (DFS) and overall survival (OS) and whether benefits are maintained across relevant patient subgroups.

Methods Studies were retrieved by searching the PubMed database and the proceedings of major conferences. We extracted hazard ratios (HR) and 95% CIs for DFS and OS from each trial and obtained pooled estimates using an inverse-variance model.

Results Thirteen studies were included in the meta-analysis (N = 22,903 patients). The pooled HR estimate was 0.83 (95% CI, 0.79 to 0.87; P < .00001) for DFS and 0.85 (95% CI, 0.79 to 0.91; P < .00001) for OS. Risk reduction was not influenced by the type of taxane, by estrogen receptor (ER) expression, by the number of axillary metastases (N1 to 3 v N4+), or by the patient's age/menopausal status. Sensitivity analysis showed that taxanes given in combination with anthracyclines, unlike sequential administration, did not significantly improve OS. However, the test for interaction showed that HR did not differ between the two schedules (P = .54). Taxane administration resulted in an absolute 5-year risk reduction of 5% for DFS and 3% for OS.

Conclusion The addition of a taxane to an anthracycline-based regimen improves the DFS and OS of high-risk EBC patients. The DFS benefit was independent of ER expression, degree of nodal involvement, type of taxane, age/menopausal status of patient, and administration schedule.

Supported by Grant No. 1044: AIRC (Associazione Italiana Ricerca sul Cancro) regional grant.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Selection of a Taxane As Well As Anthracycline for Early Breast Cancer
  Peter H. Graham
  JCO 2008 26: 2416-2417 [Full Text]

This article has been cited by other articles:

				D. Mavroudis, P. Papakotoulas, A. Ardavanis, K. Syrigos, S. Kakolyris, N. Ziras, C. Kouroussis, N. Malamos, A. Polyzos, C. Christophyllakis, et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer Ann. Onc., November 11, 2009; (2009) mdp498v1. [Abstract] [Full Text] [PDF]

				W. M. Sikov, D. S. Dizon, R. Strenger, R. D. Legare, K. P. Theall, T. A. Graves, J. S. Gass, T. A. Kennedy, and M. A. Fenton Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study J. Clin. Oncol., October 1, 2009; 27(28): 4693 - 4700. [Abstract] [Full Text] [PDF]

				D. Takabatake, N. Taira, F. Hara, T. Sien, S. Kiyoto, S. Takashima, K. Aogi, S. Ohsumi, H. Doihara, and S. Takashima Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients Jpn. J. Clin. Oncol., August 1, 2009; 39(8): 478 - 483. [Abstract] [Full Text] [PDF]

				A. Moreno-Aspitia and E. A. Perez Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545. [Abstract] [Full Text] [PDF]

				L. Gianni, J. Baselga, W. Eiermann, V. G. Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. L. Cussac, et al. Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2474 - 2481. [Abstract] [Full Text] [PDF]

				M. Hickey, M. Peate, C.M. Saunders, and M. Friedlander Breast cancer in young women and its impact on reproductive function Hum. Reprod. Update, May 1, 2009; 15(3): 323 - 339. [Abstract] [Full Text] [PDF]

				S. Jones, F. A. Holmes, J. O'Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 J. Clin. Oncol., March 10, 2009; 27(8): 1177 - 1183. [Abstract] [Full Text] [PDF]

				L. J. Goldstein, A. O'Neill, J. A. Sparano, E. A. Perez, L. N. Shulman, S. Martino, and N. E. Davidson Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197 J. Clin. Oncol., September 1, 2008; 26(25): 4092 - 4099. [Abstract] [Full Text] [PDF]

				N. C Turner and A. L Jones Management of breast cancer--Part II BMJ, July 11, 2008; 337(jul11_2): a540 - a540. [Full Text]

				M. De Laurentiis and S. De Placido In Reply J. Clin. Oncol., May 10, 2008; 26(14): 2417 - 2417. [Full Text] [PDF]

				P. H. Graham Selection of a Taxane As Well As Anthracycline for Early Breast Cancer J. Clin. Oncol., May 10, 2008; 26(14): 2416 - 2417. [Full Text] [PDF]